BARCELONA — Optovue has expanded its optical coherence tomography angiography technology with the introduction of AngioAnalytics here at the European Society of Cataract and Refractive Surgeons meeting.
This added capability provides clinicians with the ability to measure the density of blood flow in the retina, which may lead to the improved clinical management of diabetic retinopathy and age-related macular degeneration, according to a company press release.
“AngioAnalytics expands OCTA technology by introducing quantification so that changes in a patient’s retina can be tracked objectively, potentially even before the patient notices significant vision degradation. This capability allows us to optimize treatment in a way that we have not previously been able to do,” Richard Rosen, MD, said in the release.
AngioAnalytics augments the AngioVue Imaging System by creating a visual map of retinal blood flow and providing objective data with regard to flow and non-flow regions, according to the press release.
“Providing clinicians with the ability to quantify blood flow in the retina should allow for earlier and more individualized treatment without the need or cost of repeated dye injections,” Jay Wei, Optovue’s founder and chief executive officer, said in the release.
Disclosure: Rosen has financial relationships with Allergan, Clarity, Ocata Therapeutics, Opticology, Optovue, Nano Retina, Quantel, and Regeneron. Wei is Optovue’s chief executive officer.